Gene Therapy Market Analysis, Size, Growth, Share, Outlook & Forecast to 2027
The global gene therapy market size is expected to reach USD 6.6 billion by 2027, at a CAGR of 16.6% over the forecast period, according to a new report by Grand View Research, Inc. The approval of early CAR-T-based gene therapy products has created lucrative avenues in product approvals over expanded indications. Clinical trials for T-cell therapies each year has risen exponentially in the recent past. Constant developments in CAR-T cell therapy are recognized as one of the key driving factors for market growth. Although gene therapy has primarily been used for cancer treatment, it increasingly finds application in the treatment of various rare and incurable diseases. Approval of products for non-cancer applications, such as approval of Bluebird Bio’s Zynteglo in June 2019 for βthalassemia, indicates the shift in preferences of companies toward other untapped segments. Gene therapies involve complex molecules and hence manufacturing these molecules is a challenge for developers, particularly in with regard to specialized manufacturing facilities and highly skilled technical personnel. This has created lucrative avenues for contract service providers operating in the space. Gene Therapy Market Report Highlights 
Since viral vectors are the most conventional method for the delivery of genes, several operating players have designed their gene therapy programs based on viral vectors
In 2019, the lentivirus and retrovirus generated significant revenue owing to the approval of lentivirus-based Kymriah and retrovirus-based Yescarta in 2017 by the U.S. FDA
Among various indications, a majority of the revenue share is generated by various forms of cancer. This is attributed to the presence of approved products for cancer forms such as acute lymphoblastic leukemia (ALL), large B-cell lymphoma, and melanoma
North America dominated the global gene therapy market in 2019 as U.S. is the largest market for clinical trials related to gene therapy, since around 60.0% of all clinical trials in the world are carried out in the country. Moreover, FDA approval of Kymriah and Yescarta in U.S. in 2017 and Kymriah in Canada in 2018 has resulted in huge investments by sponsors and government agencies in North America
Key market players include Bluebird Bio, Novartis AG, UniQure NV, Gilead Sciences, Spark Therapeutics LLC, and Celgene Corporation
These players are engaged in signing licensing, commercialization, and development agreements with other market participants to expand their business operations in cell and gene therapy domain. For instance, Novartis Pharmaceuticals received commercialization rights for Spark Therapeutics’ Luxturna for selling the product outside U.S.
Browse Details of Report @ https://www.grandviewresearch.com/industry-analysis/gene-therapymarket
Gene Therapy Market Segmentation Gene Therapy Market Segmentation
Grand View Research has segmented the global gene therapy market on the basis of indication, vector type, and region: Gene Therapy Indication Outlook (Revenue, USD Million, 2016 - 2027)
Acute Lymphoblastic Leukemia (ALL)
Inherited Retinal Disease
Large B-cell Lymphoma
ADA-SCID
Melanoma (Lesions)
Beta-Thalassemia Major/SCD
Head & Neck Squamous Cell Carcinoma
Peripheral Arterial Disease
Spinal Muscular Atrophy (SMA)
Others
Gene Therapy Vector Type Outlook (Revenue, USD Million, 2016 - 2027)
Lentivirus
AAV
Retrovirus & Gammaretrovirus
Modified Herpes Simplex Virus
Adenovirus
Non-viral Plasmid Vector
Gene Therapy Regional Outlook (Revenue, USD Million, 2016 - 2027)
North America o
U.S.
o
Canada
Europe
Asia Pacific
o
China
o
Japan
o
Russia
o
Australia
Get Sample of Report @ https://www.grandviewresearch.com/industry-analysis/gene-therapymarket/request/rs1
Table of Content Chapter 1 Executive Summary 1.1 Market Snapshot Chapter 2 Research Methodology 2.1 Information Procurement 2.2 Information or Data Analysis 2.3 Market Formulation & Validation Chapter 3 Gene Therapy Market Variables, Trends & Scope 3.1 Market Segmentation & Scope 3.1.1 Market driver analysis 3.1.1.1 Robust gene therapy pipeline 3.1.1.2 Introduction of technological advancements 3.1.1.3 Increasing investment from the companies and partnerships 3.1.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
3.1.2 Market restraint analysis 3.1.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy 3.1.2.2 High prices of gene therapy medicines 3.1.3 Opportunity analysis 3.1.3.1 Rising investment for adoptive T cell transfer approaches of disease treatment 3.1.3.2 Facility expansion for cell and gene therapies 3.1.3.3 Technological advancements in manufacturing vectors 3.1.4 Challenge Analysis 3.1.4.1 Production capacity challenges 3.1.4.2 Manufacturing challenges pertaining to largescale production of vectors 3.1.5 Regulatory framework 3.2 Gene Therapy Market - SWOT Analysis, By Factor (Political & legal, economic and technological) 3.3 Industry Analysis - Porter’s 3.4 Pricing Analysis 3.5 Pipeline Analysis Continue………
About Grand View Research, Inc.: Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact: Sherry James Corporate Sales Specialist, USA Grand View Research, Inc Phone: 1-415- 349-0058 Toll Free: 1-888- 202-9519 Email: sales@grandviewresearch.com For More Information: http://www.grandviewresearch.com